Skip to navigation Skip to content

News release

Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity

May 25, 2025

Weston, Florida (May 23, 2025) – Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®1, in the United States, with 180 days of exclusivity.

Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.

"The launch of nilotinib highlights our commitment to providing affordable, high-quality, critical medications to patients in need," said Christine Baeder, President, Apotex USA. "By offering the first generic version of this important leukemia treatment, we improve access and outcomes for both adult and pediatric patients facing this serious disease."

Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications.

About Apotex

Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. 

Learn more about us at www.apotex.com.

All media inquiries:
Apotex Media

[email protected]

1 Tasigna® is a registered trademark of Novartis AG

Media inquries

Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.

Contact our media team

Latest news

  • Aug 12, 2026

    Apotex Announces First Quarter 2027 Results

    TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.

  • Jul 17, 2026

    Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement

    Toronto, ON, July 16, 2026. Apotex Health Corp ("Apotex" or the "Company") (TSX: APTX) today announced the successful completion of an amended and restated credit agreement ("Amended Credit Agreement"), establishing a financing framework aligned with the Company's evolution as a publicly traded, investment-grade-rated issuer.

  • Jul 8, 2026

    Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection

    Toronto, ON, July 8, 2026 – Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.